IP Library Granted Patent US 9,730,995
Granted Patent B2
US 9,730,995 · App. 14/860,210 · Granted Aug 15, 2017

Attenuated

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,730,995
App. No.
14/860,210
Granted
Aug 15, 2017
Kind
B2
Abstract

A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.

Claims (8)

1. A live attenuated Bordetella pertussis strain comprising at least a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic toxin (dnt) gene, and a heterologous ampG gene replacing the Bordetella ampG gene, wherein the strain is able to colonize and induce protective immunity against Bordetella pertussis infection in a subject when administered to the subject.

2. The live attenuated Bordetella pertussis strain of claim 1 , wherein the live attenuated Bordetella strain expresses less than 5% residual tracheal cytotoxin (TCT) activity.

3. An immunogenic composition comprising a dose of the live attenuated Bordetella pertussis strain of claim 1 and a pharmaceutically acceptable carrier.

4. The immunogenic composition of claim 3 , wherein the dose consists of 1×10 3 to 1×10 6 of the live attenuated Bordetella pertussis strain bacteria.

5. The immunogenic composition of claim 3 , wherein the dose consists of 1×10 4 to 5×10 6 of the live attenuated Bordetella pertussis strain bacteria.

6. The immunogenic composition of claim 3 , wherein the dose of the live attenuated Bordetella pertussis strain and the pharmaceutically acceptable carrier are comprised within a spray bottle or nasal inhaler.

7. The immunogenic composition of claim 3 , wherein the dose of the live attenuated Bordetella pertussis strain and the pharmaceutically acceptable carrier are formulated as a dry powder.

8. The immunogenic composition of claim 3 , wherein the dose of the live attenuated Bordetella pertussis strain and the pharmaceutically acceptable carrier are comprised within an aerosolized liquid.

Assignments (1)
SECURITY INTEREST Recorded Sep 23, 2024
From: ILIAD BIOTECHNOLOGIES, LLC
To: AVENUE CAPITAL MANAGEMENT II, L.P.
Reel/Frame 068668/0854 →